Open-Angle Glaucoma - Pipeline Review, H2 2016

Published: Aug, 2016 | Pages: 123 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Open-Angle Glaucoma - Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Open-Angle Glaucoma - Pipeline Review, H2 2016', provides an overview of the Open-Angle Glaucoma pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Open-Angle Glaucoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Open-Angle Glaucoma and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Open-Angle Glaucoma
- The report reviews pipeline therapeutics for Open-Angle Glaucoma by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Open-Angle Glaucoma therapeutics and enlists all their major and minor projects
- The report assesses Open-Angle Glaucoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Open-Angle Glaucoma

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Open-Angle Glaucoma
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Open-Angle Glaucoma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table Of Content

Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Open-Angle Glaucoma Overview 10
Therapeutics Development 11
Pipeline Products for Open-Angle Glaucoma - Overview 11
Pipeline Products for Open-Angle Glaucoma - Comparative Analysis 12
Open-Angle Glaucoma - Therapeutics under Development by Companies 13
Open-Angle Glaucoma - Therapeutics under Investigation by Universities/Institutes 15
Open-Angle Glaucoma - Pipeline Products Glance 16
Late Stage Products 16
Clinical Stage Products 17
Early Stage Products 18
Open-Angle Glaucoma - Products under Development by Companies 19
Open-Angle Glaucoma - Products under Investigation by Universities/Institutes 21
Open-Angle Glaucoma - Companies Involved in Therapeutics Development 22
Aerie Pharmaceuticals, Inc. 22
Allergan Plc 23
Amakem NV 24
Bausch & Lomb Incorporated 25
F. Hoffmann-La Roche Ltd. 26
Glaukos Corporation 27
Inotek Pharmaceuticals Corporation 28
Isarna Therapeutics GmbH 29
Kowa Company, Ltd. 30
Laboratoires Thea S.A. 31
Laboratorios Sophia S.A. de C.V. 32
Lee's Pharmaceutical Holdings Limited 33
Lexicon Pharmaceuticals, Inc. 34
Ocular Therapeutix, Inc. 35
Otsuka Holdings Co., Ltd. 36
Oxford BioMedica Plc 37
Sanofi 38
Santen Pharmaceutical Co., Ltd. 39
Senju Pharmaceutical Co., Ltd. 40
Sun Pharma Advanced Research Company Ltd. 41
Sylentis S.A.U. 42
ViSci Ltd. 43
Open-Angle Glaucoma - Therapeutics Assessment 44
Assessment by Monotherapy Products 44
Assessment by Combination Products 45
Assessment by Target 46
Assessment by Mechanism of Action 49
Assessment by Route of Administration 51
Assessment by Molecule Type 53
Drug Profiles 55
(bimatoprost + brimonidine tartarate + timolol maleate) - Drug Profile 55
Product Description 55
Mechanism Of Action 55
R&D Progress 55
(bimatoprost + timolol maleate) - Drug Profile 56
Product Description 56
Mechanism Of Action 56
R&D Progress 56
(carteolol hydrochloride + latanoprost) - Drug Profile 57
Product Description 57
Mechanism Of Action 57
R&D Progress 57
(latanoprost + netarsudil mesylate) - Drug Profile 58
Product Description 58
Mechanism Of Action 58
R&D Progress 58
(latanoprost + timolol maleate) - Drug Profile 60
Product Description 60
Mechanism Of Action 60
R&D Progress 60
(latanoprost + trabodenoson) - Drug Profile 61
Product Description 61
Mechanism Of Action 61
R&D Progress 61
AMA-0076 - Drug Profile 62
Product Description 62
Mechanism Of Action 62
R&D Progress 62
Antisense Oligonucleotides to Inhibit P16INK4a for Primary Open-Angle Glaucoma (POAG) - Drug Profile 64
Product Description 64
Mechanism Of Action 64
R&D Progress 64
bamosiran - Drug Profile 65
Product Description 65
Mechanism Of Action 65
R&D Progress 65
bimatoprost - Drug Profile 68
Product Description 68
Mechanism Of Action 68
R&D Progress 68
bimatoprost SR - Drug Profile 69
Product Description 69
Mechanism Of Action 69
R&D Progress 69
DE-117 - Drug Profile 71
Product Description 71
Mechanism Of Action 71
R&D Progress 71
decorin - Drug Profile 72
Product Description 72
Mechanism Of Action 72
R&D Progress 72
Glaucoma-GT - Drug Profile 73
Product Description 73
Mechanism Of Action 73
R&D Progress 73
ISTH-0036 - Drug Profile 74
Product Description 74
Mechanism Of Action 74
R&D Progress 74
latanoprost - Drug Profile 76
Product Description 76
Mechanism Of Action 76
R&D Progress 76
latanoprost - Drug Profile 78
Product Description 78
Mechanism Of Action 78
R&D Progress 78
latanoprost SR - Drug Profile 80
Product Description 80
Mechanism Of Action 80
R&D Progress 80
latanoprost SR - Drug Profile 81
Product Description 81
Mechanism Of Action 81
R&D Progress 81
latanoprostene bunod - Drug Profile 82
Product Description 82
Mechanism Of Action 82
R&D Progress 82
levobetaxolol hydrochloride - Drug Profile 86
Product Description 86
Mechanism Of Action 86
R&D Progress 86
LX-7101 - Drug Profile 87
Product Description 87
Mechanism Of Action 87
R&D Progress 87
MAN-01 - Drug Profile 88
Product Description 88
Mechanism Of Action 88
R&D Progress 88
MGV-354 - Drug Profile 89
Product Description 89
Mechanism Of Action 89
R&D Progress 89
netarsudil mesylate - Drug Profile 90
Product Description 90
Mechanism Of Action 90
R&D Progress 90
OPA-6566 - Drug Profile 95
Product Description 95
Mechanism Of Action 95
R&D Progress 95
PRO-067 - Drug Profile 96
Product Description 96
Mechanism Of Action 96
R&D Progress 96
R-801 - Drug Profile 97
Product Description 97
Mechanism Of Action 97
R&D Progress 97
RG-4929 - Drug Profile 99
Product Description 99
Mechanism Of Action 99
R&D Progress 99
ripasudil - Drug Profile 100
Product Description 100
Mechanism Of Action 100
R&D Progress 100
RO-5093151 - Drug Profile 102
Product Description 102
Mechanism Of Action 102
R&D Progress 102
SAR-366234 - Drug Profile 103
Product Description 103
Mechanism Of Action 103
R&D Progress 103
Sepetaprost - Drug Profile 104
Product Description 104
Mechanism Of Action 104
R&D Progress 104
SNJ-1656 - Drug Profile 105
Product Description 105
Mechanism Of Action 105
R&D Progress 105
trabodenoson - Drug Profile 107
Product Description 107
Mechanism Of Action 107
R&D Progress 107
travoprost - Drug Profile 110
Product Description 110
Mechanism Of Action 110
R&D Progress 110
travoprost SR - Drug Profile 111
Product Description 111
Mechanism Of Action 111
R&D Progress 111
travoprost XR - Drug Profile 113
Product Description 113
Mechanism Of Action 113
R&D Progress 113
Open-Angle Glaucoma - Dormant Projects 115
Open-Angle Glaucoma - Discontinued Products 117
Open-Angle Glaucoma - Product Development Milestones 118
Featured News & Press Releases 118
Apr 26, 2016: Inotek Pharmaceuticals Announces Poster Presentations on Trabodenoson at the ARVO 2016 Annual Meeting 118
Apr 11, 2016: Inotek Pharmaceuticals Announces the Journal of Ocular Pharmacology and Therapeutics has Published its Phase 2 Data for Trabodenoson in Patients with Glaucoma and Ocular Hypertension 118
Mar 03, 2016: Aerie Pharmaceuticals Announces Availability on Its Website of Abstracts to be Presented at the American Glaucoma Society 26th Annual Meeting 119
Feb 22, 2016: Aerie Pharmaceuticals Announces Four New Abstracts to be Presented at the American Glaucoma Society 26th Annual Meeting Next Week 119
Mar 10, 2010: Qlt Announces Phase II Clinical Trial Results And Development Plans For The Punctal Plug Delivery System 120
Jul 28, 2009: Qlt Announces Interim Data From A Phase II Clinical Trial And A Device Study For A Punctal Plug Drug Delivery System 121
Appendix 122
Methodology 122
Coverage 122
Secondary Research 122
Primary Research 122
Expert Panel Validation 122
Contact Us 122
Disclaimer 123

List Of Tables

Number of Products under Development for Open-Angle Glaucoma, H2 2016 11
Number of Products under Development for Open-Angle Glaucoma - Comparative Analysis, H2 2016 12
Number of Products under Development by Companies, H2 2016 13
Number of Products under Development by Companies, H2 2016 (Contd..1) 14
Number of Products under Investigation by Universities/Institutes, H2 2016 15
Comparative Analysis by Late Stage Development, H2 2016 16
Comparative Analysis by Clinical Stage Development, H2 2016 17
Comparative Analysis by Early Stage Development, H2 2016 18
Products under Development by Companies, H2 2016 19
Products under Development by Companies, H2 2016 (Contd..1) 20
Products under Investigation by Universities/Institutes, H2 2016 21
Open-Angle Glaucoma - Pipeline by Aerie Pharmaceuticals, Inc., H2 2016 22
Open-Angle Glaucoma - Pipeline by Allergan Plc, H2 2016 23
Open-Angle Glaucoma - Pipeline by Amakem NV, H2 2016 24
Open-Angle Glaucoma - Pipeline by Bausch & Lomb Incorporated, H2 2016 25
Open-Angle Glaucoma - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016 26
Open-Angle Glaucoma - Pipeline by Glaukos Corporation, H2 2016 27
Open-Angle Glaucoma - Pipeline by Inotek Pharmaceuticals Corporation, H2 2016 28
Open-Angle Glaucoma - Pipeline by Isarna Therapeutics GmbH, H2 2016 29
Open-Angle Glaucoma - Pipeline by Kowa Company, Ltd., H2 2016 30
Open-Angle Glaucoma - Pipeline by Laboratoires Thea S.A., H2 2016 31
Open-Angle Glaucoma - Pipeline by Laboratorios Sophia S.A. de C.V., H2 2016 32
Open-Angle Glaucoma - Pipeline by Lee's Pharmaceutical Holdings Limited, H2 2016 33
Open-Angle Glaucoma - Pipeline by Lexicon Pharmaceuticals, Inc., H2 2016 34
Open-Angle Glaucoma - Pipeline by Ocular Therapeutix, Inc., H2 2016 35
Open-Angle Glaucoma - Pipeline by Otsuka Holdings Co., Ltd., H2 2016 36
Open-Angle Glaucoma - Pipeline by Oxford BioMedica Plc, H2 2016 37
Open-Angle Glaucoma - Pipeline by Sanofi, H2 2016 38
Open-Angle Glaucoma - Pipeline by Santen Pharmaceutical Co., Ltd., H2 2016 39
Open-Angle Glaucoma - Pipeline by Senju Pharmaceutical Co., Ltd., H2 2016 40
Open-Angle Glaucoma - Pipeline by Sun Pharma Advanced Research Company Ltd., H2 2016 41
Open-Angle Glaucoma - Pipeline by Sylentis S.A.U., H2 2016 42
Open-Angle Glaucoma - Pipeline by ViSci Ltd., H2 2016 43
Assessment by Monotherapy Products, H2 2016 44
Assessment by Combination Products, H2 2016 45
Number of Products by Stage and Target, H2 2016 47
Number of Products by Stage and Mechanism of Action, H2 2016 50
Number of Products by Stage and Route of Administration, H2 2016 52
Number of Products by Stage and Molecule Type, H2 2016 54
Open-Angle Glaucoma - Dormant Projects, H2 2016 115
Open-Angle Glaucoma - Dormant Projects (Contd..1), H2 2016 116
Open-Angle Glaucoma - Discontinued Products, H2 2016 117